DSOPAL: Oedematous Lower Limb Subcutaneous Drainage in Palliative Care

Sponsor
University Hospital, Limoges (Other)
Overall Status
Terminated
CT.gov ID
NCT02473744
Collaborator
(none)
15
7
1
23.8
2.1
0.1

Study Details

Study Description

Brief Summary

  • Background : Edema of lower extremities is a concern ranging from 19 % to 60% of palliative cancer patients. Lymphedema decreases mobility, induces pain, impacts daily activities, esthetic and behavior. Usual treatment is based on diuretics and physiotherapy but is often unsuccessful. In case of conventional treatment failure, in palliative care, subcutaneous drainage can be discussed with the patients. The technique is simple, easy to use but remains off the record. Since 2004, 23 cases were reported with various methods. All the cases reported were undertaken with various technical approaches and efficacy criteria.

  • Purpose : Investigator hypothesize that the subcutaneous drainage of edema (SDO) is effective in case of refractory lymphedema of the lower limbs in palliative care and leads to an improvement in QOL in terms of behavioral and autonomy.

Condition or Disease Intervention/Treatment Phase
  • Other: subcutaneous drainage
N/A

Detailed Description

• Abstract : In palliative care, lymphedema results from various associations of cancer, hypoalbuminemia, electrolytic disturbances or organ failure. The lymphatic circulation cannot be summarized by the Starling's equation and obstruction cannot explain everything. An interstitial hypothesis underlines the role of the lymphatic pump and edema volume can be a crucial point. The SDO, via the direct liquid removal, can restore the lymphatic pump function. This volumetric effect can explain the long time effect of the SDO and the large range of liquid amount reported in effective SDO. The superficial lymphatic system, in the superficial layer of derma, drains 80 % of lymph flow. In edema, the increased volume leads to the creation of subcutaneous interconnected lacunas. The subcutaneous site for drainage is justified.

After topic anesthesia, three subcutaneous channels are created on the ankle's medial face of the edematous limbs and liquids are absorbed by pads. An additional drainage can be done on the external face of the thigh with liquid collecting bags in bedridden patients.

The study includes clinical examination, total and segmental bioelectrical impedance measured at J0, J4 and on exit or at J7 at the latest and daily weight, umbilic abdominal perimeters and segmental circumferences and QOL evaluation before and after SDO. Bioelectrical impedance is collected from hand-foot, thigh root-foot and under patella calf - foot electrodes. Segmental circumferences are collected at thigh, calf and ankle points identified from bone relief distance.

Study Design

Study Type:
Interventional
Actual Enrollment :
15 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Oedematous Lower Limb Subcutaneous Drainage in Palliative Care
Actual Study Start Date :
Jul 27, 2015
Actual Primary Completion Date :
Jul 20, 2017
Actual Study Completion Date :
Jul 20, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Oedematous lower limb subcutaneous drainage

In case of lymphoedema in palliative situation, a subcutaneous drainage can be performed. It is a simple method, easy to use. After topic analgesia, three subcutaneous channels are created and an absorbent pad collects the lymphatic fluid.

Other: subcutaneous drainage
After topic analgesia, three subcutaneous channels are created and an absorbent pad collects the lymphatic fluid.

Outcome Measures

Primary Outcome Measures

  1. Karnofsky's scale [7 days]

    Change in autonomy evaluated by Karnofsky's scale between Day 7 and Day 0

Secondary Outcome Measures

  1. Karnofsky's scale [4 Days]

    Change in autonomy evaluated by Karnofsky's scale between Day 4 and Day 0

  2. The 15th item of the European Organisation for Research and Treatment of Cancer quality of life questionnaires of palliative cancer care patients (EORTC QLQ C15 PAL), [4 days and 7 days]

    Changes in quality of life evaluated by the 15th item of the EORTC QLQ C15 PAL scale between between Day 4/Day 7 and Day 0

  3. Modify Dermatology Life Quality Index (MDLQI) [4 days and 7 days]

    Changes in quality of life related to lymphedema evaluated by the MDLQI between Day 4/Day 7 and Day 0

  4. Verbal numeric scale for pain [4 days and 7 days]

    Changes in pain evaluated by the verbal numeric scale between Day 4/Day 7 and Day 0

  5. Bioelectrical impedance analysis of lower limbs, calves and thighs [4 days and 7 days]

    Changes in bioelectrical impedance of lower limbs, calves and thighs between Day 4/Day 7 and Day 0.

  6. Segmental limb circumferences measurement [4 days and 7 days]

    Variation of the physical measures in time. Changes in segmental limb circumferences between Day 4/Day 7 and Day 0

  7. Abdominal perimeter measurement [4 days and 7 days]

    Variation of the physical measures in time. Changes in abdominal perimeter between Day 4/Day 7 and Day 0

  8. Weight measurement [4 days and 7 days]

    Variation of the physical measures in time. Changes in weight between Day 4/Day 7 and Day 0

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥ 18

  • palliative care patients

  • Karnofsky Scale < 50%

  • Uni or bilateral lower limb oedema even if associated with lumbar or pelvi-scrotal oedema or ascitis whatever etiology involved (cancer, organ failure, hypoalbuminemia…)

  • Effective Social security regimen affiliation

  • Signed informed consent

Exclusion Criteria:
  • Refusal to take part in the study

  • Local anesthesic contraindication

  • Infected skin lesions.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University hospital Bordeaux France 33000
2 University hospital Limoges France 87042
3 University hospital Nantes France 40031
4 Hospital Perigueux France 24019
5 Joseph Ducuing hospital Toulouse France 31027
6 University hospital Toulouse France 31059
7 Hospital Valenciennes France 59300

Sponsors and Collaborators

  • University Hospital, Limoges

Investigators

  • Principal Investigator: Bertrand SARDIN, MD, University Hospital, Limoges

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Limoges
ClinicalTrials.gov Identifier:
NCT02473744
Other Study ID Numbers:
  • I14010 DSOPAL
First Posted:
Jun 17, 2015
Last Update Posted:
Nov 14, 2017
Last Verified:
Nov 1, 2017
Keywords provided by University Hospital, Limoges
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 14, 2017